



1634
#15
CD

1600

CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 09/635,027C
Filing Date: 08/04/2000
Date Processed by STIC: 12/31/02

RECEIVED

JAN 06 2003

TECH CENTER 1600/2900

STIC Contact: Mark Spencer, 703-308-4212

Nature of Problem:

The CRF (was):

- ☐ (circle one) Damaged or Unreadable (for Unreadable, see attached)
- ☐ Blank (no files on CRF) (see attached)
- ☐ Empty file (filename present, but no bytes in file) (see attached)
- ☐ Virus-infected. Virus name: _____ The STIC will not process the CRF.
- ☐ Not saved in ASCII text
- ☐ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should **only** be the Sequence Listing.
- ☒ Did not contain a Sequence Listing. (see attached sample) - Please see sample of proper Sequence Listing attached
- ☐ Other: _____

**PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.
SEE BELOW FOR ADDRESS:**

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service , or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

09/6350270

NF-kappa B sequence on step 63 of original application was obtained from HIV-1 (nt 349-374, nt 9434- 9458) as shown on pages 8 and 11 of the sequence listing.

09/635027C

K03455. Human immunodeficiency virus type 1 [gi:1906382]

Related Sequences,

Protein, PubMed, Taxonomy

LOCUS HIVHXB2CG 9719 bp ss-RNA VRL 19-AUG-1999
DEFINITION Human immunodeficiency virus type 1 (HXB2), complete genome;
HIV1/HTLV-III/LAV reference genome.
ACCESSION K03455 M38432
VERSION K03455.1 GI:1906382
KEYWORDS TAR protein; acquired immune deficiency syndrome; complete genome;
env protein; gag protein; long terminal repeat (LTR); pol protein;
polyprotein; proviral gene; reverse transcriptase; transactivator.
SOURCE Human immunodeficiency virus type 1.
ORGANISM Human immunodeficiency virus type 1
Viruses; Retrovirus; Retroviridae; Lentivirus; Primate
lentivirus group.
REFERENCE 1 (bases 493 to 674; 9577 to 9718)
AUTHORS Ratner,L., Haseltine,W., Patarca,R., Livak,K.J., Starcich,B.,
Josephs,S.F., Doran,E.R., Rafalski,J.A., Whitehorn,E.A.,
Baumeister,K., Ivanoff,L., Petteway,S.R. Jr., Pearson,M.L.,
Lautenberger,J.A., Papas,T.S., Ghrayeb,J., Chang,N.T., Gallo,R.C.
and Wong-Staal,F.
TITLE Complete nucleotide sequence of the AIDS virus, HTLV-III
JOURNAL Nature 313 (6000), 277-284 (1985)
MEDLINE 85111123
PUBMED 2578615
REFERENCE 2 (bases 1 to 653)
AUTHORS Starcich,B., Ratner,L., Josephs,S.F., Okamoto,T., Gallo,R.C. and
Wong-Staal,F.
TITLE Characterization of long terminal repeat sequences of HTLV-III
JOURNAL Science 227 (4686), 538-540 (1985)
MEDLINE 85090465
REFERENCE 3 (sites)
AUTHORS Allan,J.S., Coligan,J.E., Barin,F., McLane,M.F., Sodroski,J.G.,
Rosen,C.A., Haseltine,W.A., Lee,T.H. and Essex,M.
TITLE Major glycoprotein antigens that induce antibodies in AIDS patients
are encoded by HTLV-III
JOURNAL Science 228 (4703), 1091-1094 (1985)
MEDLINE 85192537
REFERENCE 4 (sites)
AUTHORS Sodroski,J., Patarca,R., Rosen,C., Wong-Staal,F. and Haseltine,W.
TITLE Location of the trans-activating region on the genome of human
T-cell lymphotropic virus type III
JOURNAL Science 229 (4708), 74-77 (1985)
MEDLINE 85244627
REFERENCE 5 (sites)
AUTHORS Arya,S.K., Guo,C., Josephs,S.F. and Wong-Staal,F.
TITLE Trans-activator gene of human T-lymphotropic virus type III
(HTLV-III)
JOURNAL Science 229 (4708), 69-73 (1985)

<110> Smith, John; Smithgene Inc.
 <120> Example of a Sequence Listing
 <130> 01-00001
 <140> PCT/EP98/00001
 <141> 1998-12-31
 <150> US 08/999,999
 <151> 1997-10-15
 <160> 4
 <170> PatentIn version 2.0
 <210> 1
 <211> 389
 <212> DNA
 <213> Paramecium sp.
 <220>
 <221> CDS
 <222> (279)...(389)
 <300>
 <301> Doc. Richard
 <302> Isolation and Characterization of a Gene Encoding a
 Protease from Paramecium sp.
 <303> Journal of Genes
 <304> 1
 <305> 4
 <306> 1-7
 <307> 1988-06-31
 <308> 123456
 <309> 1988-06-31
 <400> 1
 agctgtagtc attcctgtgt cctcttctct ctgggcttct caccctgcta atcagatctc 60
 agggagagtg tcttgacctt cctctgcctt tgcagcttca caggcaggca ggcaggcagc 120
 tgaatgtggca attgctggca gtgccacagg cttttcagcc aggccttaggg tgggttcgcg 180
 cgcggcgcg 5
 cggccctct cgcgctctc tcgcgctct ctctcgtct cctctcgtc 240

Appendix 3, page 2.

ggacctgatt aggtgagcag gaggagggggg cagtttagc atg gtt tca atg ttc agc 296
Met Val Ser Met Phe Ser

ttg tct ttc aaa tgg cct gga ttt tgt ttg ttt gtt tgt ttg ttc caa 344
Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val Cys Leu Phe Phe Gln

tgt ccc aaa gtc ctc ccc tgt cac tca tca ctg cag ccg aat ctt 389
Cys Pro Lys Val Leu Pro Cys His Ser Ser Leu Gln Pro Asn Leu

<210> 2
<211> 37
<212> PRT
<213> Paramecium sp.

<400> 2
Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu
1 5 10 15

Phe Val Cys Leu Phe Gln Cys Pro Lys Val Leu Pro Cys His Ser Ser
20 25 30

Leu Gln Pro Asn Leu
35

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<221> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

<400> 3
Met Val Asn Leu Glu Pro Met His Thr Glu Ile
1 5 10

<210> 4
<400> 4
000

[Annex VIII follows]

identifiers and the accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M, when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO:#:	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

<212>	Type	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	M
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	M
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

		in feature	base was used in a sequence
<223>	Other Information	Other relevant information; four lines maximum	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA
<300>	Publication Information	Leave blank after <300>	0
<301>	Authors	Preferably max of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials	0
<302>	Title		0
<303>	Journal		0
<304>	Volume		0
<305>	Issue		0
<306>	Pages		0
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MM-yyyy or Season-yyyy	0
<308>	Database Accession Number	Accession number assigned by database including database name	0
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MM-yyyy	0
<310>	Patent Document Number	Document number; for patent-type citations only. Specify as, for example, US 07/999,999	0

<311>

Patent Filing
Date

Document filing
date, for patent-
type citations only;
specify as yyyy-mm-dd

<312>

Publication Date

Document publication
date, for
patent-type
citations only;
specify as yyyy-mm-dd

<313>

Relevant
Residues

FROM (position) TO
(position)

<400>

Sequence

SEQ ID NO should
follow the
numeric identifier
and should appear
on the line pre-
ceding the actual
sequence

5. Section 1.024 is revised to read as follows:

1.024 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.021(c) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;